Nektar Therapeutics NKTR
NASDAQ NKTR
$43.58 -3.41 (-7.26%)
At close: Oct 2, 2026 · 4:00 PM EDT

Nektar Therapeutics (NKTR) Return on Capital Employed [ROCE] (2011 - 2026)

Updated

Nektar Therapeutics' Return on Capital Employed [ROCE] came in at -16.40% for Q2 2026, up 46.38 percentage points from -62.78% a year earlier and up 12.61 percentage points from the prior quarter.

Analysis

Nektar Therapeutics (NKTR) Return on Capital Employed [ROCE] (2011 - 2026) Analysis & Trends

For FY2025, Nektar Therapeutics' Return on Capital Employed [ROCE] was -58.72%, down 22.39 percentage points from FY2024.

  • Return on Capital Employed [ROCE] carries a five-year change of -32.83 percentage points (FY2020 to FY2025).
  • Going back by year, Return on Capital Employed [ROCE] was -36.33% in FY2024 (+16.08 pp), -52.42% in FY2023 (-7.94 pp), -44.48% in FY2022 (-8.58 pp) and -35.90% in FY2021 (-10.01 pp).
  • The Q2 2026 figure represents the highest quarterly Return on Capital Employed [ROCE] since Q1 2019.
  • Year-over-year, Return on Capital Employed [ROCE] increased in five of the last eight quarters, with an average year-over-year change of +10.36 percentage points.
  • The fastest year-over-year change in Return on Capital Employed [ROCE] over five years came in Q2 2026 (a gain of 46.38 percentage points), and the weakest in Q2 2022 (a drop of 25.39 percentage points).
  • Business Quant data shows NKTR's Return on Capital Employed [ROCE] at -29.00% (Q1 2026), -59.03% (Q4 2025) and -52.15% (Q3 2025) in the three quarters before Q2 2026.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROCE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 46.74%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 17.83%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 17.92%
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 6.28%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 19.32%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 9.54%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 16.66%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -5.97%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 11.86%
10 Nektar Therapeutics 1.44 Bn -328.37 Mn - -16.40%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -16.40%
Mar 31, 2026 -29.00%
Dec 31, 2025 -59.03%
Sep 30, 2025 -52.15%
Jun 30, 2025 -62.78%
Mar 31, 2025 -54.66%
Dec 31, 2024 -43.02%
Sep 30, 2024 -59.31%
Jun 30, 2024 -52.37%
Mar 31, 2024 -47.71%
Dec 31, 2023 -71.48%
Sep 30, 2023 -67.92%
Jun 30, 2023 -61.19%
Mar 31, 2023 -68.42%
Dec 31, 2022 -55.51%
Sep 30, 2022 -59.20%
Jun 30, 2022 -59.17%
Mar 31, 2022 -46.95%
Dec 31, 2021 -40.12%
Sep 30, 2021 -37.48%
API Access

Nektar Therapeutics Return on Capital Employed [ROCE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-capital-employed-%5Broce%5D&ticker=NKTR&period=max&api_key=YOUR_API_KEY